Ilana Hellmann

Meir Medical Center — Israel

Medicine · Health Sciences

5h-index169citations26works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(15), Chronic Lymphocytic Leukemia Research(5), Chronic Myeloid Leukemia Treatments(4), Histone Deacetylase Inhibitors Research(4), Neutropenia and Cancer Infections(4)

Publications26 total

Disease status at initiation of blinatumomab and depth of response after cycle 1 are associated with survival in Philadelphia chromosome positive B cell acute lymphoblastic leukemia patients treated with blinatumomab and tyrosine kinase inhibitors
Blood·2025
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study
Blood Advances·2024· 5 citedOpen Access
Guilt and Gratitude: Staying in Touch After Cancer Treatment
2024
Gift of Truth
Journal of Clinical Oncology·2023· 1 cited
Guilt and Gratitude
Journal of Clinical Oncology·2022· 1 cited
Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group
Blood·2022· 1 cited
Yoga As Possible Non-Medical Intervention to Improve Quality of Life of Patients with Myelodysplastic Syndromes - a Feasibility Report
Blood·2022
Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study
Blood·2022
Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study
Blood·2021· 4 cited
First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study
Blood·2020· 4 cited
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3‐ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission
European Journal Of Haematology·2020· 3 cited
Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long‐term follow‐up of a multi‐center prospective study
American Journal of Hematology·2019· 1 cited
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission—a multi-center historical control study
Annals of Hematology·2019· 17 cited
Midostaurin in Combination with Intensive Chemotherapy is Safe and Associated with Improved Remission Rates and Higher Transplantation Rates in First Remission-A Multi-Center Historical Control Study
Clinical Lymphoma Myeloma & Leukemia·2019· 3 cited
PF287 MIDOSTAURIN IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IS SAFE AND ASSOCIATED WITH IMPROVED REMISSION AND HIGHER TRANSPLANT RATES IN REMISSION ‐ A MULTI‐CENTER HISTORICAL CONTROL STUDY
HemaSphere·2019· 2 citedOpen Access
Adding Midostaurin to Intensive Chemotherapy in FLT3-Positive AML Patients. Results from a Multicenter Historical-Controlled Study
Blood·2018· 2 cited
A Nationwide Observational Study of Ponatinib in CML Patients Outside of Clinical Trials- The Israeli Experience
Clinical Lymphoma Myeloma & Leukemia·2016
Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis
Anti-Cancer Drugs·2016· 2 cited
A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia
Blood·2015
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the “3 + 7” induction regimen for acute myeloid leukemia
American Journal of Hematology·2015· 29 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Yishai Ofran(17), Yakir Moshe(11), Ofir Wolach(11), Tsila Zuckerman(9), Ron Ram(8), Tamar Tadmor(7), Ronit Leiba(7), Chezi Ganzel(7), Pia Raanani(6), Itai Levi(6), Moshe E. Gatt(5), Ariela Arad(5), Najib Dally(5), Tamar Berger(5), Uri Rozovski(5), Sigal Tavor(5), Jonathan Canaani(5), Moshe Grunspan(5), Drorit Merkel(4), Anatoly Nemets(4)